Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Provided By PR Newswire
Last update: Nov 11, 2024
Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled
Read more at prnewswire.com0.94
-0.08 (-7.84%)
1.79
+0.01 (+0.56%)
Find more stocks in the Stock Screener
